CJC-1295 + Ipamorelin
Also known as CJC-1295 + IPA
Last reviewed September 26, 2026
This combination pairs a GHRH analog with a selective growth-hormone secretagogue, studied for whether engaging two complementary steps in the release cascade differs from either alone.
Mechanism of action
Research pairs a releasing-hormone analog with a ghrelin-receptor secretagogue, studied for combined action on the pituitary signaling behind endogenous hormone release.
- Dual PathwayCombines a releasing-hormone analog with a secretagogue, each studied for a distinct step in the release cascade.
- Pulsatile SupportExplored for whether the pairing preserves the body's natural pulsatile rhythm of secretion.
- Route studied
- Subcutaneous
- Receptor class
- GHRH-R + GHS-R1a
- Research status
- Early clinical
CJC-1295 has been evaluated in a randomized controlled trial in healthy adults, and Ipamorelin has been characterized as a selective growth hormone secretagogue, but the combination itself has not been established in large-scale clinical trials and neither component is regulator-approved.
What the research covers
What research examines
- Prolonged GH and IGF-I secretion with CJC-1295 in healthy adults
- Selective GH release via ghrelin-receptor agonism with Ipamorelin
- Combined GHRH-R and GHS-R1a signaling on pituitary GH release
- Preservation of pulsatile GH secretion patterns
- Body composition and lean-mass research contexts
- Recovery and musculoskeletal applications discussed in sports medicine reviews
Reported effects in studies
- Human safety data for the combination are limited
- Adverse events are not summarized for the blend in the cited studies
- CJC-1295 has been reported to produce prolonged elevation of GH and IGF-I
- Safety of unapproved peptides for athletic performance has been reviewed in sports medicine literature
- Synthetic GHRH analogs are targets of anti-doping detection methods
What research protocols have used
Research protocols have used 200–600 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorResearched alongside
Cited research
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
The Journal of clinical endocrinology and metabolism · 2006 · RCT · PubMed 16352683
- Ipamorelin, the first selective growth hormone secretagogue.
European journal of endocrinology · 1998 · PubMed 9849822
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
Translational andrology and urology · 2020 · Review · PubMed 32257855
- Advances in the detection of growth hormone releasing hormone synthetic analogs.
Drug testing and analysis · 2021 · PubMed 34665524
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · 2026 · Review · PubMed 41966639
Questions about CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin, also called CJC-1295 + IPA, is a research blend pairing CJC-1295, a long-acting analog of growth hormone-releasing hormone (GHRH), with Ipamorelin, a selective growth hormone secretagogue. The combination is studied for whether engaging two complementary steps in the growth hormone release cascade differs from using either compound alone. It is supplied for laboratory research use only.
The blend targets two receptor classes. CJC-1295 acts at the GHRH receptor (GHRH-R), the pathway through which releasing hormone signals the pituitary. Ipamorelin acts at the ghrelin receptor (GHS-R1a), a separate route that also stimulates growth hormone release. Research has explored whether this dual-pathway approach supports endogenous hormone release while preserving the natural pulsatile rhythm of secretion, rather than producing a constant signal.
A randomized controlled trial in healthy adults reported that CJC-1295 produced prolonged stimulation of growth hormone and IGF-I secretion. Ipamorelin was described in 1998 as the first selective growth hormone secretagogue. Reviews have discussed growth hormone secretagogues in body composition research, and recent sports medicine and orthopaedic reviews have examined peptides of this type in recovery and musculoskeletal contexts. Evidence for the combination specifically remains limited.
Human safety data for the combination are limited, and adverse events for the blend are not summarized in the cited studies. CJC-1295 has been reported to cause prolonged elevation of GH and IGF-I, which is relevant to monitoring in research settings. Recent reviews have assessed the safety of unapproved peptides used for musculoskeletal injury and athletic performance, and synthetic GHRH analogs are subject to anti-doping detection methods.
Research protocols have used 200–600 mcg per administration by the subcutaneous route, 5 days per week in a pre-sleep timing, arranged in 12-week blocks followed by 4 weeks off. These figures describe what protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.
Ask about CJC-1295 + Ipamorelin
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
CJC-1295 + Ipamorelin at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Performance
$119.00
$189.00










